FDA Improves Drug Review Timeframes, Aims For Original PDUFA Standard
This article was originally published in The Tan Sheet
Executive Summary
After an almost two-year hiatus from strict adherence to Prescription Drugs User Fee Act review timeframes, Office of New Drugs Director John Jenkins has told review staff that, once again, they should strive to meet the user fee deadlines
You may also be interested in...
CDER's Generational Shift Brings New Reviewers With Little Experience
The past two fiscal years have seen great gains in the number of new employees hired in FDA's Center for Drug Evaluation and Research, but the result is a relatively under-experienced staff: 38 percent of employees in both CDER and the Office of New Drugs have less than two years of on-the-job experience
"Complete Response" Transparency Could Spur Better Applications - Jenkins
Office of New Drugs Director John Jenkins sees a possible side benefit for FDA of more efficient drug approval processes should the agency's transparency initiative lead to the public release of "complete response" letters
FDA Misses User Fee Goals As Resources Tighten For Reviews, SPAs
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program